Skip to main content

McKesson Corporation U.S. Pharmaceutical revenue

  • MCK · NYSE
  • Distribution
  • Health Care Distributors
  • S&P 500
$1091.50−1.22%Close 17 Nov 2026 · USD · Market value $126.0B

U.S. Pharmaceutical revenue at McKesson Corporation came to $90.0B for the quarter to 30 Jun 2025, up 25.4% from a year earlier.

As McKesson Corporation reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 6 Aug 2025.

By quarter

$61.9BDec 2022$61.7BMar 2023$67.2BJun 2023$69.8BSep 2023$73.0BDec 2023$68.8BMar 2024$71.7BJun 2024$85.7BSep 2024$87.1BDec 2024$83.2BMar 2025$90.0BJun 2025
McKesson Corporation U.S. Pharmaceutical revenue, every reported period
Period endingU.S. Pharmaceutical revenueChange on a yearFiled
30 Jun 2025$90.0Bup 25.4%6 Aug 2025
31 Mar 2025$83.2Bup 20.9%8 May 2025
31 Dec 2024$87.1Bup 19.3%5 Feb 2025
30 Sep 2024$85.7Bup 22.9%6 Nov 2024
30 Jun 2024$71.7Bup 6.8%7 Aug 2024
31 Mar 2024$68.8Bup 11.5%7 May 2024
31 Dec 2023$73.0Bup 17.9%7 Feb 2024
30 Sep 2023$69.8B—1 Nov 2023
30 Jun 2023$67.2B—2 Aug 2023
31 Mar 2023$61.7B—8 May 2023
31 Dec 2022$61.9B—1 Feb 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of McKesson Corporation: International revenue · North American Pharmaceutical revenue · Oncology & Multispecialty revenue · Medical-Surgical Solutions revenue · Prescription Technology Solutions revenue · financial statements

Every KPI and segment of MCK, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.